GLP-1 Drug Semaglutide Extends Lifespan and Slows Aging in Older Mice

Clinical trial designers evaluating the next generation of GLP-1 receptor agonists face a shifting baseline: deciding whether to measure these compounds purely as metabolic interventions, or to test them explicitly as anti-aging therapeutics. Their next wave of human longevity trials now has a specific biological mechanism to target, following a controlled demonstration that semaglutide extends lifespan and preserves cognitive function in mice beyond what can be explained by weight loss alone.

Published September 2 in the journal Nature, a study led by researchers at the University of California, Berkeley, tested whether the widespread clinical benefits of GLP-1 drugs stem from a fundamental slowing of the physiological aging process. The research team administered semaglutide—the active ingredient in the blockbuster diabetes and obesity medications Ozempic and Wegovy—to 20-month-old female mice, an age roughly equivalent to 60 human years.[1][2]

The mice that received daily semaglutide injections for the rest of their lives reached a median lifespan of 834 days, compared to 742 days for the control group receiving saline. This 12 percent extension, amounting to nearly 100 additional days of life, was accompanied by measurable improvements in coordination, muscle function, and glucose metabolism.[2][3][4]

Because GLP-1 receptor agonists suppress appetite, the treated mice naturally reduced their food intake by 24 percent. Calorie restriction is a well-documented intervention known to extend lifespan across multiple species, raising the immediate question of whether the drug was simply acting as a chemical diet. To isolate the drug's specific effects, the researchers set up a parallel five-month experiment where an untreated control group was placed on a strict 24 percent calorie-restricted diet to perfectly match the intake of the semaglutide group.[2][3]

While both the diet-restricted mice and the semaglutide-treated mice lived longer than baseline controls, their physiological responses diverged sharply. The mice on the calorie-restricted diet exhibited a slowed metabolic rate, a common biological response to conserve energy during food scarcity. In contrast, the mice receiving semaglutide maintained a normal metabolic rate.[2]

The drug-treated group also outperformed the diet-only group in cognitive and behavioral metrics. Semaglutide-treated mice demonstrated higher levels of exploratory behavior, superior spatial memory, and better blood-sugar maintenance than their calorie-restricted counterparts. According to Danica Chen, a professor of metabolic biology and nutrition at UC Berkeley and the study's corresponding author, these differences suggest that GLP-1 drugs tap into biological pathways independent of calorie restriction.[2]

Genetic and cellular analyses confirmed that the drug blunted several hallmarks of natural aging. The treated animals showed reduced genomic instability, lower systemic inflammation, and a decrease in cellular senescence—the accumulation of damaged cells that stop dividing but refuse to die. The researchers also observed increased markers of neural stem-cell activity and the formation of new neurons in the dentate gyrus, a brain region critical for memory formation.[1][2][3]

The findings offer a potential unifying theory for the expanding list of GLP-1 benefits, which now includes FDA approvals for reducing cardiovascular risk and slowing kidney disease progression. Rafael de Cabo, a senior investigator at the National Institute on Aging, noted that most chronic diseases are deeply rooted in the aging process itself. "If GLP-1 agonists do indeed slow it down, then a wide range of clinical benefits is exactly what you'd expect to see," de Cabo said.[3][4]

The evidence currently stops at the cage, and the researchers are explicit about the study's limitations. The experiment was conducted exclusively on female mice to avoid the aggressive behaviors that male mice often exhibit when housed together, leaving the drug's effects on male longevity untested. Furthermore, the dosing regimen began in late life and continued daily until death, a protocol that would equate to decades of continuous injections in humans.[4]

Translating a 12 percent lifespan extension to human populations will require long-term clinical tracking that spans decades. However, the immediate impact of the Berkeley data is on the design of upcoming trials. By demonstrating that semaglutide acts as a gerotherapeutic capable of modulating nutrient sensors and genetic regulators of aging, the study provides the mechanistic foundation needed to test GLP-1 compounds directly against neurodegenerative decline and frailty in older adults.[1]